Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer

SIMPLE SUMMARY: Recently, immunotherapy has presented new opportunities for clinical development in the treatment of non-small cell lung cancer (NSCLC). Although effective in sustaining overall survival in several clinical trials, not all the NSCLC patients respond to these treatments. Thus, a bette...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghini, Veronica, Laera, Letizia, Fantechi, Beatrice, del Monte, Francesca, Benelli, Matteo, McCartney, Amelia, Tenori, Leonardo, Luchinat, Claudio, Pozzessere, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760033/
https://www.ncbi.nlm.nih.gov/pubmed/33265926
http://dx.doi.org/10.3390/cancers12123574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760033/
https://www.ncbi.nlm.nih.gov/pubmed/33265926
http://dx.doi.org/10.3390/cancers12123574

Ejemplares similares